Q4 2016 Specialty Pharmacy Pipeline Report
The increase in the number of specialty drugs and the cost of those drugs continues to be a major concern for all payers of health care claims.
Our Q4-2016 Specialty Pharmacy Pipeline Report provides an up to date summary of 18 drugs in the specialty pharmacy pipeline with expected approval dates between now and the end of 2017.
The report includes:
- Each drug’s generic name and brand name (if known)
- The drug’s medical indication such as breast cancer, ALS (Lou Gehrig’s disease), ovarian cancer etc.
- The expected cost of each drug, ranging up to $300,000 a year
- Recommendations and comments from our pharmacy management Resources® partner, Excelsior Solutions
We think you will find it helpful and informative. Download the new Q4 2016 Specialty Pharmacy Pipeline Report here for insight into how drugs in the pipeline will impact pharmacy costs and strategies to reduce these costs.